Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma ...Middle East

DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted...

Read More Details
Finally We wish PressBee provided you with enough information of ( Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma )

Also on site :

• 21-year-old Baloch student becomes another victim of extrajudicial killing by Pakistani forces
• Gold miners killed in pit collapse in war-torn Sudan
• This Week on 'Beyond the Gates' Welcome to Fairmont Crest